<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01678404</url>
  </required_header>
  <id_info>
    <org_study_id>MZL 131I-rituximab RIT</org_study_id>
    <nct_id>NCT01678404</nct_id>
  </id_info>
  <brief_title>131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma</brief_title>
  <official_title>A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Cancer Center Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marginal zone B-cell lymphoma (MZL) is a lymphoma originated from B-cell in lymph node with
      variable differentiation status, which is distributed to a variety of organs.

      A high response rate and long term survival is possible through surgery or radiation therapy
      alone in the case of limited disease. However frequent relapse and progression is observed
      despite of long term survival. The treatment after relapse has not been established yet.

      So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or
      relapsed patients with MZL.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>up to 5 years</time_frame>
    <description>International Working Group Response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>up to 5 years</time_frame>
    <description>grading the adverse events using CTCAE version 4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Relapsed or Refractory Marginal Zone B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>131I-rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>131I-rituximab</intervention_name>
    <arm_group_label>131I-rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed marginal zone B-cell lymphoma

          -  relapsed or refractory patients after treatment including chemotherapy, radiation
             therapy, and surgery

          -  Eastern Cooperative Oncology Group performance status ≤ 2

          -  age≥ 20 years

          -  More than one measurable lesion (More than 2cm sized lesion in conventional CT scan,
             More than 1cm sized lesion in spiral CT or contrast-enhanced PET/CT )

          -  Adequate renal function (serum creatinine ≤ 2.0 mg/dl or Ccr ≥ 60 ml/min)

          -  Adequate hepatic function (serum bilirubin ≤ 2.0 mg/dl , AST/ALT ≤ 3 upper normal
             limit)

          -  Adequate bone marrow reservoir (ANC ≥1,500/㎕, platelet count≥ 75,000/㎕)

          -  patient who agree the purpose and intention of this clinical trial

        Exclusion Criteria:

          -  recent (&lt;5 years) history of other malignancy or unrecovered from the disease
             (appropriately treated skin cancer and uterine cervix carcinoma in situ are excluded)

          -  hemodynamically unstable due to the recent (&lt;12 months) history of severe heart
             disease such as myocardial infarction

          -  acute complications of severe lung or metabolic disease

          -  Combined severe neurological or psychiatric disease

          -  Unrecovered from infection or other medical disease

          -  Recent (&lt;30 days) history of enrollment of other clinical trial

          -  Pregnant or breast-feeding woman

          -  women of childbearing potential and men not employing adequate contraception at least
             for 1 year

          -  Previous history drug allergy to the content of 131I-rituximab

          -  Infection(sepsis, pneumonia, viral infection, etc) (inactivated hepatitis B carrier
             can be enrolled)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hye Jin Kang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hye Jin kang, M.D.</last_name>
    <phone>+82-2-970-1289</phone>
    <email>mdhyejin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong-Yeop Shin, M.D.</last_name>
    <phone>+82-2-970-1246</phone>
    <email>baramg@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences</name>
      <address>
        <city>Seoul</city>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Jin Kang, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Dong-Yeop Shin, M.D.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hye Jin Kang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung Hyun Yang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Im Il Na, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyo-Rak Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong-Yeop Shin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang Moo Lim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Change Woon Choi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung Il Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilhan Lim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung-Sook Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2012</study_first_submitted>
  <study_first_submitted_qc>September 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2012</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

